The abstract is read at the publisher; the summary is JClub's.
Endogenous GLP-1R and GLP-2R signaling is essential to protect mice from T cell–mediated intestinal injury, with increased damage in Glp1r -/- , Glp2r -/- , and Gcg Gut-/- mice.
- Why it matters: Immune-driven enteropathy lacks clear links to gut-derived glucagon-like peptide receptor activity, despite prior preclinical evidence that GLP-1R/GLP-2R agonism can reduce intestinal damage.
- What they did: Mice with Glp1r -/- , Glp2r -/- , or selective intestinal proglucagon loss (Gcg Gut-/- ) were assessed after αCD3-induced injury, and separate or combined teduglutide (GLP-2R) and semaglutide (GLP-1R) were tested in Gcg Gut-/- mice.
- The result: GLP-2R and GLP-1R agonists attenuated αCD3-induced intestinal damage in Gcg Gut-/- mice, supporting distinct protective roles and therapeutic potential for glucagon-like peptides in T cell–mediated mucosal injury.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.